Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy
These findings underscore the potential of iGN as a strategy to enhance cancer immunotherapy, particularly when used in combination with immune checkpoint blockade, to bolster anti-tumor immune responses and improve therapeutic outcomes.
Authors
- Shinya Wada (ORCID: https://orcid.org/0000-0002-7932-159X)
- Mayumi Niimura
- Saisai Liu
- Mayuko Shimoda (ORCID: https://orcid.org/0009-0009-6681-502X)
- Akihiro Nita (ORCID: https://orcid.org/0000-0003-2647-5445)
- Hiroyuki Oshiumi (ORCID: https://orcid.org/0000-0003-1567-8722)
- Tomoko Hayashi (ORCID: https://orcid.org/0000-0002-9589-8348)
- Narumi Harada (ORCID: https://orcid.org/0000-0002-4100-0184)
- Yasuhisa Sakamoto (ORCID: https://orcid.org/0000-0003-1833-6197)
- Asuka Iwamoto (ORCID: https://orcid.org/0000-0001-6969-2314)
- Chanida Thinyakul (ORCID: https://orcid.org/0000-0002-2927-0595)
- Hiroyuki Shinchi (ORCID: https://orcid.org/0000-0001-5204-9170)
- Ayato Maeda
- Yasuo Suda (ORCID: https://orcid.org/0000-0003-4306-9705)
- Toshiro Moroishi (ORCID: https://orcid.org/0000-0001-6419-3882)
- Masahiro Wakao (ORCID: https://orcid.org/0000-0003-2554-8825)
- Yohei Kanamori (ORCID: https://orcid.org/0009-0003-4062-5910)
- Dennis A. Carson (ORCID: https://orcid.org/0000-0001-5273-0804)
- Haruka Ohara
- Koki Murata
Institutions
- Kagoshima University (JP)
- University of California San Diego (US)
- The University of Tokyo (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1038/s43856-025-01102-3
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Japan Agency for Medical Research and Development
- Hoansha Foundation
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Precursory Research for Embryonic Science and Technology